sanofi aventis
Post on 20-Dec-2014
1.428 Views
Preview:
DESCRIPTION
TRANSCRIPT
Research and DevelopmentSanofi-Aventis
BS4Danil+Eric+Karim+Andrew+David
What is R&D for you?
Telecom
Pharmacy
Car maintenance
Construction
Agriculture
Main R&D ratios in Accounting
• R&D Intensity R&D expenses / Sales
• R&D per employee R&D expenses / N of employees
• R&D growth rate R&D expenses Year 2/ R&D expenses Year 1
Lev and Sougiannis, 1996, Studies Outcome for US & UK
R&D investments
Market Value=
R&D Intensity for different businesses
R&D Scorecard – UK DTI
Sanofi-AventisCase Study
Sanofi
French
Pharmacy
Founded in 1976 by Elf
Number of acquisitions
Sanofi
Aventis 2003 2002 2001 Sanofi-Synthelabo 2003 2002 2001
Net sales 17 815 20 622 22 941 Net sales 8 048 7 448 6 488Co-promotion income 252 161 Cost of goods sold (1 428) (1 378) (1 253)Production costs and expenses (5 377) (6 578) (7 943) Gross profit 6 620 6 070 5 235
(5 365) (6 866) (7 178) Research and development expenses(1 316) (1 218) (1 031)Research and development (2 924) (3 420) (3 481) Selling and general expenses (2 477) (2 428) (2 306)Restructuring expenses (251) (68) (50) Other operating income/(expense), net 248 190 208Goodwill amortization (480) (1 021) (650) Operating profit 3 075 2 614 2 106Operating income 3 670 2 830 3 639 Intangibles – amortization and impairment(129) (129) (68)
(107) 51 85 Financial income/(expense), net 155 85 102Interest (expense) income – net (151) (309) (704) Income before tax and exceptional items3 101 2 570 2 140
(501) 1 120 (134) Exceptional items 24 10 2812 911 3 692 2 886 Income taxes (1 058) (746) (842)
Provision for income taxes (929) (1 430) (1 111) Net income before income from equity investees, goodwill amortization and minority interests2 067 1 834 1 579Minority interests (29) (86) (142) Income from equity investees, net 20 20 14Preferred remuneration (52) (85) (128) Goodwill amortization (8) (8) (7)Net income 1 901 2 091 1 505 Net income before minority interests 2 079 1 846 1 586
Minority interests (3) (87) (1)Net income 2 076 1 759 1 585
Aventis
French
Pharmacy
Therapeutic proteins
Founded 1999
Aventis
Aventis 2003 2002 2001 Sanofi-Synthelabo 2003 2002 2001
Net sales 17 815 20 622 22 941 Net sales 8 048 7 448 6 488Co-promotion income 252 161 Cost of goods sold (1 428) (1 378) (1 253)Production costs and expenses (5 377) (6 578) (7 943) Gross profit 6 620 6 070 5 235Selling, general and administrative costs and other operating income (expenses)(5 365) (6 866) (7 178) (1 316) (1 218) (1 031)Research and development (2 924) (3 420) (3 481) Selling and general expenses (2 477) (2 428) (2 306)Restructuring expenses (251) (68) (50) 248 190 208Goodwill amortization (480) (1 021) (650) Operating profit 3 075 2 614 2 106Operating income 3 670 2 830 3 639 (129) (129) (68)Equity in earnings of affiliated companies(107) 51 85 Financial income/(expense), net 155 85 102Interest (expense) income – net (151) (309) (704) 3 101 2 570 2 140Miscellaneous non-operating income and expenses – net(501) 1 120 (134) Exceptional items 24 10 281Income before taxes and minority interests2 911 3 692 2 886 Income taxes (1 058) (746) (842)Provision for income taxes (929) (1 430) (1 111) 2 067 1 834 1 579Minority interests (29) (86) (142) 20 20 14Preferred remuneration (52) (85) (128) Goodwill amortization (8) (8) (7)Net income 1 901 2 091 1 505 2 079 1 846 1 586
Minority interests (3) (87) (1)Net income
Net SalesR&D expensesR&D intensityR&D growth
2001
Sanofi
Net SalesR&D expensesR&D intensityR&D growth
2001 2002
6448(1253)16%
Sanofi
Net SalesR&D expensesR&D intensityR&D growth
2001 2002 2003
6448(1253)16%
7448(1378)16%18%
Sanofi
Net SalesR&D expensesR&D intensityR&D growth
2001 2002 2003
6448(1253)16%
7448(1378)16%18%
2004
8048(1428)16%8%
Sanofi
Net SalesR&D expensesR&D intensityR&D growth
2001 2002 2003
6448(1253)16%
7448(1378)16%18%
2004
8048(1428)16%8%
2001
Sanofi
Aventis
Net SalesR&D expensesR&D intensityR&D growth
2001 2002 2003
6448(1253)16%
7448(1378)16%18%
2004
8048(1428)16%8%
2002 2001
22941(3481)15%
Net SalesR&D expensesR&D intensityR&D growth
Sanofi
Aventis
Net SalesR&D expensesR&D intensityR&D growth
2001 2002 2003
6448(1253)16%
7448(1378)16%18%
2004
8048(1428)16%8%
2003 2002 2001
20622(3420)17%-2%
22941(3481)15%
Net SalesR&D expensesR&D intensityR&D growth
Sanofi
Aventis
Net SalesR&D expensesR&D intensityR&D growth
2001 2002 2003
6448(1253)16%
7448(1378)16%18%
2004
8048(1428)16%8%
2003 2002 2001
20622(3420)17%-2%
22941(3481)15%
2004
17815(2924)16%-15%
Net SalesR&D expensesR&D intensityR&D growth
Sanofi
Aventis
Net SalesR&D expensesR&D intensityR&D growth
2001 2002 2003
6448(1253)16%
7448(1378)16%18%
2004
8048(1428)16%8%
2003 2002 2001
20622(3420)17%-2%
22941(3481)15%
2004
17815(2924)16%-15%
Net SalesR&D expensesR&D intensityR&D growth
Sanofi
Aventis
Sanofi-AventisSanofi-Aventis 2004
Net sales 15 043Cost of goods sold (3 753)Gross profit 11 290Research and development expenses (7 455)Selling and general expenses (4 500)Other operating income/(expense), net 360Operating profit (305)Amortization and impairment of intangibles (1 563)Financial income/(expense), net 25Income before tax and exceptional items (1 843)Exceptional items (402)
Income taxes (819) R&D Intensity ( % Sales) 49,6%
Net income before income from equity investees, goodwill amortization and minority interests(3 064)Income from equity investees, net (261)Goodwill amortization (292)Net income before minority interests (3 617)Minority interests 7Net income (3 610)
2004
Sanofi-Aventis
Net SalesR&D expensesR&D intensity
15043(7455)50%
2004
Net SalesR&D expensesR&D intensity
2001 2002 2003
6448(1253)16%
7448(1378)16%
2004
8048(1428)16%
2003 2002 2001
20622(3420)17%
22941(3481)15%
2004
17815(2924)16%
Net SalesR&D expensesR&D intensity
15043(7455)50%
Paradox
?One Manager Banker
2003
8048(1428)16%
17815(2924)16%
15043(7455)50%
2004
320 pages
(thank you prof. Capkun)
200320022001
20622(3420)17%
22941(3481)15%
2004
17815(2924)16%
…. ($5046)
R&D expenses
($2409)
+
Sanofi-AventisAventis
R&D expenses
Net Sales
R&D intensity
($7455)
15043
50%
Sanofi-Aventis
2004
Net SalesR&D expensesR&D intensity
15043(7455)50%
2006 2007
28052(4537)16%
27568(4575)16%
2008
28373(4430)16%
Class QUIZ
?
Class QUIZ
?What are the three main ratio used in accounting for analysing R&D expenditure?
R&D Intensity R&D per employee R&D growth rate
Class QUIZ
?Name three industries with high R&D intensity.
PharmacyElectronicsSoftware
Class QUIZ
?How should R&D expenses be treated in accounting while merging two companies?
1. Estimate Market value of R&D of acquired company up to date
2. Add it to current yearly R&D expenses of acquiring company
top related